Positive allosteric modulators of the ionotropic glutamate receptor-2 (GluA2) are promising compounds for the treatment of cognitive disorders, e.g. Alzheimer's disease. These modulators bind within the dimer interface of the LBD (ligand-binding domain) and stabilize the agonist-bound conformation slowing receptor desensitization and/or deactivation. In the present study, we employ isothermal titration calorimetry to determine binding affinities and thermodynamic details of binding of modulators of GluA2. A mutant of the LBD of GluA2 (LBD-L483Y-N754S) that forms a stable dimer in solution was used. The potent GluA2 modulator BPAM-97 was used as a reference compound. Evidence that BPAM-97 binds in the same pocket as the wellknown GluA2 modulator cyclothiazide was obtained from Xray structures. The LBD-L483Y-N754S:BPAM-97 complex has a K d of 5.6 μM ( H = − 4.9 kcal/mol, − T S = − 2.3 kcal/mol; where 1 kcal≈4.187 kJ). BPAM-97 was used in a displacement assay to determine a K d of 0.46 mM ( H = − 1.2 kcal/mol, − T S = − 3.3 kcal/mol) for the LBD-L483Y-N754S:IDRA-21 complex. The major structural factors increasing the potency of BPAM-97 over IDRA-21 are the increased van der Waals contacts to, primarily, Met 496 in GluA2 imposed by the ethyl substituent of BPAM-97. These results add important information on binding affinities and thermodynamic details, and provide a new tool in the development of drugs against cognitive disorders.
INTRODUCTION
AMPA(α-amino-3-hydroxy-5-methylisoxazole-4-propionicacid) receptors (GluA1-4; ionotropic glutamate receptors 1-4) are tetrameric ligand-gated ion channels that mediate influx and efflux of metal ions across post-synaptic membranes in the mammalian brain in response to glutamate [1] . Each subunit comprises an extracellular N-terminal domain, an LBD (ligand-binding domain), a membrane-spanning region and an intracellular Cterminal domain. In the full-length homotetrameric GluA2, four LBDs are arranged as a dimer of dimers with a two-fold symmetry axis [2] . The LBD constitutes an open clamshell-like apo structure [3] . The agonist-binding site is positioned in a cavity between the so-called D1 and D2 domains that are connected via a hinge region. Upon glutamate binding, the LBD adopts a closed clamshell-like structure as a result of movement of the D2 domain. This rearrangement presumably places a conformational strain on the channel pore that leads to channel opening and influx of ions [3] .
Two different mechanisms may lead to channel closing. Deactivation leads to closure of the ion channel after removal of glutamate from the receptor and involves an opening of the clamshell-like structure and release of the bound agonist. Desensitization, on the other hand, results in closure of the channel with glutamate still bound to the receptor and involves a rearrangement of the interface between the D1 domains of the LBD dimers while keeping the closed clamshell-like structure intact [4] [5] [6] . Positive allosteric modulators can potentiate GluA2 currents in two ways. Modulators such as aniracetam and CX614 primarily stabilize the agonist-bound closed clamshell conformation and thereby block deactivation, whereas modulators such as CTZ (cyclothiazide) and IDRA-21 ( Figure 1 ) primarily act by stabilizing the D1-D1 interface and hence slow desensitization [5] [6] [7] [8] .
An important factor in the development of allosteric modulators is knowledge about binding affinities, as well as the thermodynamic contributions to the binding energy from formation of hydrogen bonds, van der Waals interactions and desolvation of the modulator. In recent years ITC (isothermal titration calorimetry) has become applied more frequently in the drug development process, exactly for its ability to quantify the specific enthalpy and entropy contributions to the binding energy (reviewed in [9] ). The solubility of the majority of positive allosteric modulators of AMPA receptors is in the micromolar range, which is a challenge for achieving the saturating conditions needed in ITC. Also, membrane-bound receptors are not easily purified in the relatively large quantities required for ITC experiments. The GluAs provide a circumvention of the latter problem, as soluble constructs of the LBDs can be purified in large amounts. To date, several crystal structures of isolated LBDs in complex with allosteric modulators are available [5] [6] [7] [8] [10] [11] [12] [13] [14] . However, another complication arises because the LBD construct is predominantly monomeric in solution with a K d of dimerization of 6 mM that decreases to 1.2 μM in the presence of CTZ [6] . Hence measuring modulator affinity towards the monomeric LBD might not resemble the biologically relevant situation of the dimeric membrane-anchored LBD. In the present study we used the fact that the L483Y mutation dramatically strengthens the D1-D1 interface in the LBD, lowering the K d of dimerization of the GluA2 LBD to 30 nM without altering the modulator binding cavity [6] . By introducing the L483Y mutation to the LBD (Figure 2A ) we isolated the event of modulator binding to a preformed cavity in the dimer interface of the LBD.
Alternative splicing leads to formation of the kinetically distinct flip and flop AMPA receptor isoforms [15, 16] . Owing to sterical hindrance from Asn 754 in the flop isoform, modulators such as CTZ and IDRA-21 preferentially potentiate the flip isoform (Ser 754 ) of GluA2. Therefore in most structural studies of the GluA2 LBD in complex with modulators, a N754S mutation has been introduced into the GluA2 LBD [6] [7] [8] .
The previously synthesized soluble and potent GluA2 modulator BPAM-97 [17] (Figure 1 ) was applied to directly measure the thermodynamics of its complex formation with the L483Y and N754S double mutant of the GluA2 LBD (LBD-L483Y-N754S) by ITC. BPAM-97 is a small-sized benzothiadiazine dioxide structurally related to IDRA-21. Information on the molecular contacts between modulator and protein was obtained by X-ray crystallography. Furthermore, we used BPAM-97 in a displacement assay [18] to determine the thermodynamics of binding of the less-soluble but much investigated modulator IDRA-21, a benzothiadiazine dioxide tightly related to diazoxide [19] .
The results, combined with structural analysis, provide a molecular explanation for the dramatic increase in the binding affinity of BPAM-97 relative to IDRA-21 and, to our knowledge, the first information on thermodynamics of positive allosteric modulators.
EXPERIMENTAL Protein expression and purification
The rat GluA2 LBD S1S2 pET-22b( + ) construct was used as a template to generate the GluA2 LBD-L483Y-N754S mutant using the QuikChange ® protocol (Stratagene). The resulting plasmid was transformed into the Escherichia coli strain Origami B (DE3) (Novagen). Cells were grown to a D 600 of 0.9 in LB (LuriaBertani) medium, subsequently cooled to 20
• C and 0.5 mM IPTG (isopropyl β-D-thiogalactopyranoside) was added. After an expression period of 20 h, cells were pelleted and the protein was purified by Ni 2 + -affinity chromatography. The N-terminal Histag was removed by trypsin digestion and the cleaved protein was finally purified by anion-exchange chromatography and SEC (size-exclusion chromatography). Expression and purification of the rat GluA2 LBD-N754S mutant were performed essentially as described previously [7] .
The presence of monomers and dimers in solution was verified by DLS (dynamic light scattering) and by SEC-MALS (SEC followed by multi-angle light scattering) (Supplementary Table  S1 at http://www.BiochemJ.org/bj/441/bj4410173add.htm).
Crystallization
Co-crystallization was performed at 6
• C using the hanging drop vapour-diffusion method. The drops consisted of 1 μl of protein solution and 1 μl of reservoir solution. The protein solution contained 6 mg/ml LBD-L483Y-N754S in 10 mM Hepes, 20 mM NaCl, 1 mM EDTA, and 1 mM L-glutamate. For co-crystallization experiments 0.5-1 mg of either CTZ (Sigma) or BPAM-97 was added to 150 μl of protein solution and the mixture was incubated for 72 h prior to crystallization. Crystallization conditions were 15.2 % PEG [poly(ethylene glycol)] 4000, 0.3 M lithium sulfate and 0.1 M phosphate citrate, pH 4.5 (BPAM-97) and 20 % PEG 4000, 0.3 M ammonium sulfate and 0.1 M phosphate citrate, pH 4.5 (CTZ). Crystals were soaked in reservoir buffer containing 20 % glycerol and flash-cooled in liquid nitrogen.
Data collection, structure determination and refinement
Diffraction data were collected at MAX-lab (Lund, Sweden). The LBD-L483Y-N754S:BPAM-97 and LBD-L483Y-N754S:CTZ data were scaled and indexed using iMosflm [20] and solved by molecular replacement using Phaser [21] with the LBD-N754S structure (PDB code 3H6T, molecule A for BPAM-97; PDB code 1LBC, molecule A for CTZ) as the search model. ARP/wARP [22] was used for initial model building and further model building was done in Coot [23] . Refinements were performed using Phenix [24] . Topology and parameter files for ligands were obtained using Prodrg [25] for BPAM-97 and the Schrödinger software (Maestro, version 9.1) for CTZ. Data and refinement statistics are shown in Table 1 . Domain closures were calculated using Dyndom [26] .
ITC
ITC was performed with an ITC200 MicroCalorimeter (GE Healthcare) with a cell volume of 200 μl at 25
• C. For direct measurements the calorimeter cell was filled with 45 μM LBD-L483Y-N754S dimer in ITC buffer [100 mM Hepes (pH 7), 100 mM NaCl, 2 mM KCl and 5 mM L-glutamate at 25
• C] or 72.5 μM LBD-N754S monomer in ITC buffer. The protein concentration was determined based on both amino acid analysis and UV absorption. For titration of the LBD-L483Y-N754S dimer, 20 injections of 1.54 mM BPAM-97 in ITC buffer were performed at 3 min intervals with 0.5 μl in the first injection and 2 μl in the subsequent injections. For titration of the LBD-N754S monomer, 20 injections of 2.0 mM BPAM-97 in ITC buffer were performed at 3 min intervals with 0.5 μl in the first injection and 2 μl in the subsequent injections. For the displacement assay [18] with racemic IDRA-21, the cell was filled with 45 or 54 μM LBD-L483Y-N754S dimer in ITC buffer supplemented with 1.8 or 1.6 mM IDRA-21 respectively, followed by 20 injections of 1.0 mM BPAM-97 in ITC buffer at 3 min intervals with 0.5 μl in the first injection and 2 μl in the subsequent injections. For the displacement assay with CTZ, the cell was filled with 15 μM LBD-L483Y-N754S in ITC buffer supplemented with 50 μM CTZ. The heat of dilution from injecting ligand into buffer was subtracted before the fitting process. The data analysis was performed with the Origin 7.0 software (MicroCal) for ITC using a single-binding-site model for the direct assays with BPAM-97 [27] . For displacement assays, data were fitted to a competitive binding model [18] , also using the Origin 7.0 software. The first data point in the analysis was discarded. The reported H, − T S, K d and n are mean values obtained from four or five experiments.
RESULTS

Structures of LBD-L483Y-N754S in complex with CTZ and BPAM-97
The structure of the extensively studied modulator CTZ in complex with the GluA2 LBD-N754S has previously been determined, showing that two molecules of CTZ bind at the interface between two molecules of GluA2, forming a dimer [6] . Furthermore, GluA2 LBD-L483Y has been reported to form a dimer similar to that of the GluA2 LBD [6] . To ensure that a similar GluA2 dimer is formed with LBD-L483Y-N754S and that CTZ binds in an identical manner with LBD-L483Y-N754S, we determined an atomic resolution crystal structure of LBD-L483Y-N754S in co-complex with glutamate and CTZ. Data collection and refinement statistics are shown in Table 1 . As expected, LBD-L483Y-N754S is present in crystals as a dimer, and the structure of the LBD-L483Y-N754S complex with CTZ is very similar to the previously published structure of the LBD-N754S complex with CTZ (PBD codes 3H6T and 1LBC) (Supplementary Figure  S1 at http://www.BiochemJ.org/bj/441/bj4410173add.htm). The binding mode of CTZ in LBD-L483Y-N754S, together with a simulated annealing 2F o − F c OMIT electron-density map, is shown in Supplementary Figure S2 ( [6, 7] . Also, the region of the L483Y mutation is very similar in LBD-L483Y-N754S to that in LBD-N754S (Supplementary Figure S3 at http://www.BiochemJ.org/bj/441/ bj4410173add.htm). The closure of domain D2 towards D1 in LBD-L483Y-N754S is 21.3
• and 22.1
• for the A and B chains respectively compared with the apo structure (PDB code 1FTO, molecule A).
Next, we determined a high-resolution structure of LBD-L483Y-N754S with glutamate and BPAM-97 ( Figure 2 and Table 1 ). The complex crystallizes as a similar dimer to that of LBD-L483Y-N754S with CTZ. The domain closure is 20.5
• and 19.5
• for the A and B chains respectively. These values are comparable with those seen in the crystal structure of GluA2 LBD with glutamate only (19.1-21.1
• ) [3] . Two molecules of BPAM-97 are found at the dimer interface (Figure 2A) , and BPAM-97 adopts a binding mode close to that of IDRA-21 [8] . BPAM-97 binds with the fluorine atom orientated towards Ser 497 ( Figure 2C ). The sulfonamide oxygen atom of one BPAM-97 molecule forms a potential hydrogen bond to an ordered water molecule (W1 Figure 2D ).
Binding affinities of BPAM-97 towards LBD-L483Y-N754S and LBD-N754S
The dimeric LBD-L483Y-N754S protein represents a binding environment close to that of the dimer of dimers structure present in the full-length GluA2 receptor and provides the opportunity to isolate the event of modulator binding to a preformed cavity in the dimer interface of the LBD. Figure 3B ). Hence, a 4-5-fold lower binding affinity of the modulator is seen for the monomeric form of the GluA2 LBD than for the preformed dimeric LBD. It has not been possible for us to explain the discrepancy in stoichiometry of BPAM-97 binding to the LBD-N754S monomer and the LBD-L483Y-N754S dimer. However, the value of n does not seem to affect the determined values of H, S and K d . No additional density was located in the structure of LBD-L483Y-N754S with BPAM-97 that could indicate the presence of an additional BPAM-97 molecule. Also, setting the n value to a fixed number led to poor curve fitting. Therefore a plausible explanation for the observed stoichiometry might lie within determination of protein concentrations. 
Figure 3 ITC studies of BPAM-97 binding to GluA2 LBD-L483Y-N754S and GluA2 LBD-N754S, as well as IDRA-21 binding to GluA2 LBD-L483Y-N754S
Raw data (top panels) and isotherms (bottom panels) are presented. The graphs show that heat is developed after each injection and that the signal is diminished when the protein becomes 3 μM in the presence of CTZ. However, as commercially available CTZ is usually synthesized as a mixture of four diastereomeric racemates it was not possible to estimate a K d for the LBD-L483Y-N754S:CTZ complex [28] . Similarly, a racemic mixture of IDRA-21 was used in the present study. Only the (S)-enantiomer of IDRA-21 is seen to bind in the crystal structure [8] . As the pure enantiomer rapidly epimerizes in solution reforming the mixture of isomers [29] , the equilibrium might be changed upon binding of the (S)-enantiomer of IDRA-21 to the protein and, hence, it might be plausible to consider IDRA-21 as one compound in our ITC experiments.
DISCUSSION
The first observation of the biological impact of a benzothiadiazine dioxide on AMPA receptors was made with diazoxide [30] . This compound was able to reduce glutamate receptor desensitization and to prolong post-synaptic currents in rat hippocampal neurons [30, 31] . Other representatives of this chemical class, clinically used as diuretics (thiazides), were subsequently discovered as inhibitors of the rapid glutamate receptor desensitization of AMPA receptors, among which CTZ ( Figure 1 ) was identified as the most potent compound [31, 32] . In contrast with 3-alkyl-substituted benzothiadiazine dioxides (such as IDRA-21; Figure 1 ) that possess an asymmetric centre at the 3-position and therefore may exist as racemic mixtures, small-sized molecules devoid of a chiral carbon atom at the 3-position and bearing only a short alkyl chain at the 4-position (such as BPAM-97; Figure 1 ) are achiral compounds. Moreover, they possess, like IDRA-21, a favourable physicochemical profile for crossing biological membranes and reaching the central nervous system. BPAM-97 was shown to be active in an object recognition test in rats at low doses, demonstrating cognition-enhancing effects in vivo after oral administration [17] . Using ITC for the optimization of lead compounds has proven a powerful tool in drug development throughout the last decade [9] . However, most AMPA-receptor-positive allosteric modulators have either very low solubility or low potency. We used the pHSol server [33] to predict intrinsic solubility of modulators and compared these with reported potencies. With a predicted maximum solubility of 7.5 mM and an EC 50 of 33 μM, BPAM-97 stood out as a suitable candidate for ITC experiments. Isolated LBDs are monomeric in solution, forming dimers when combined with modulators. By applying the novel dimeric GluA2 LBD-L483Y-N754S flip version of the GluA2 LBD, it was possible to essentially isolate the event of modulator binding from the event of dimer formation in solution. The co-crystal structures of LBD-L483Y-N754S in complex with CTZ and BPAM-97 state that essential modulator contacts are preserved using the LBD-L483Y-N754S protein.
We measured a K d of 5.6 μM for LBD-L483Y-N754S:BPAM-97, and a K d of 25 μM for LBD-N754S:BPAM-97. Thus BPAM-97 displays a 4-5-fold increase in affinity for the LBD-L483Y-N754S over LBD-N754S. As very few contacts are formed between BPAM-97 and one monomer, it seems unlikely that BPAM-97 binds to the monomer first and then leads to dimer formation. Hence it is more likely that it helps to stabilize the dimer and thereby shifts the monomer-dimer equilibrium. Data from DLS and SEC-MALS ( Supplementary Table S1 ) support that LBD-L483Y-N754S is primarily seen as a dimer, whereas LBD-N754S is primarily monomeric. Addition of BPAM-97 results in dimerization of LBD-N754S, as apparent from the increase in molecular mass (Supplementary Table S1 ).
The modulatory potency (EC 50 ) of BPAM-97 has previously been determined as 33 μM [17] , showing that binding affinity and potency is within the same range. IDRA-21 has been demonstrated as a more potent AMPA receptor potentiator than the parent compound diazoxide [34] . In spite of a modest in vitro activity IDRA-21, but not CTZ, was found to be effective in vivo at enhancing cognition performance in animal models of cognitive impairments [19, 35] , making IDRA-21 a model compound for further developments. Even though IDRA-21 is unsuitable for ITC owing to low solubility combined with low affinity, it binds to the LBD in a similar manner to that of BPAM-97 ( Figure 2D ). Therefore we used BPAM-97 to displace IDRA-21, and thereby determined the otherwise non-obtainable lowaffinity K d of 0.46 mM for IDRA-21. This is in line with the previously published EC 5X for IDRA-21 of 509 μM [17] and reveals a substantially lower enthalpy relative to BPAM-97.
The binding modes of BPAM-97 and IDRA-21 are similar, but, in contrast with IDRA-21, BPAM-97 forms a weak fluoro-atommediated hydrogen bond to Ser 497 . The influence of the nature of the substituent at the 7-position of benzothiadiazine dioxides has previously been explored [17] . The substituent with the highest modulatory potency was found to be a halogen atom, preferably a fluorine or a chlorine atom (F Cl>Br>I). Therefore this cannot account for the higher binding affinity of BPAM-97 relative to IDRA-21, as replacing the fluoro substituent of BPAM-97 with chlorine (as in IDRA-21) only marginally lowers the potency of the compounds [17] . Structure-activity studies demonstrated that optimal activity on AMPA receptors in vitro was achieved when the 2-position remained free of substituent, when the 3-position bore only hydrogen atoms or a very short alkyl chain (i.e. methyl), and when a short alkyl chain (i.e. methyl, ethyl or isopropyl) was introduced at the 4-position [36, 37] . BPAM-97 is an example of such a compound that at the second nitrogen atom of the thiadiazine ring (the 4-position) bears a short alkyl substituent. Such a structural feature is not encountered with the first generation of benzothiadiazine-type of AMPA receptor modulators [30] [31] [32] . The N4 ethyl moiety of BPAM-97 reaches into a subsite, which is flanked by Met 496 and thus optimizes the protein-modulator contacts ( Figure 2D) . Hence, contacts of the N4 ethyl moiety provide a probable explanation for the improved binding affinity and potency compared with IDRA-21. This is corroborated by the observation that replacing the ethyl moiety with a methyl group lowers the potency of the 7-chlorinesubstituted form of BPAM-97 [17] . Taken together, the major factors increasing potency of BPAM-97 over IDRA-21 are by far the increased van der Waals contacts to, primarily, the Met 496 backbone imposed by the ethyl substituent.
In conclusion, in the present study we show that the GluA2 LBD-L483Y-N754S construct provides a novel and effective receptor model system for the characterization of lead modulator compounds by combining the use of ITC and X-ray crystallography. In addition, as BPAM-97 has the required solubility and affinity for the feasibility of ITC experiments, this compound can also be used for determination of binding constants of other less ITC-suitable positive allosteric modulators capable of being displaced by BPAM-97. The structure of the LBD-L483Y-N754S (in cyan and salmon) in complex with CTZ (in yellow) and the structure of LBD-N754S in complex with CTZ (PDB code 3H6T; in white) are shown. 1 To whom correspondence should be addressed (email jsk@farma.ku.dk). The co-ordinates and structure factors have been deposited in the RCSB Protein Data Bank (PDB) under accession codes 3TDJ (for GluA2 LBD-L483Y-N754S-BPAM-97) and 3TKD for (GluA2 LBD-L483Y-N754S-CTZ).
c The Authors Journal compilation c 2012 Biochemical Society Table S1 Verification of GluA2 LBD-L483Y-N754S dimer and GluA2 LBD-N754S monomer by DLS and SEC-MALS Protein solutions (1 mg/ml) were prepared in 100 mM Hepes (pH 7), 100 mM NaCl, 2 mM KCl and 5 mM L-glutamate unsupplemented or supplemented with 150 μM BPAM-97. The solutions were analysed by DLS in a Dynapro Titan (Wyatt) DLS instrument and by SEC-MALS in an Agilent 1200 system equipped with a TSK SW 3000 column (Agilent). Pd, polydispersity; R, hydrodynamic radius; MW, molecular mass. The LBD-L483Y-N754S is primarily seen as a dimer, whereas LBD-N754S is primarily monomeric. Addition of BPAM-97 results in dimerization of LBD-N754S, as apparent from the increase in molecular mass (DLS). 
Figure S4 ITC data of CTZ displacement by BPAM-97
The GluA2 LBD-L483Y-N754S dimer was used in the present study. Raw data (top panels) and isotherms (bottom panels) are represented. The graph shows that heat is developed after each injection and that the signal is diminished when the protein becomes saturated with ligand. The K d of LBD-L483Y-N754S:BPAM-97 was increased to 9.3 μM in the presence of CTZ. However, as commercially available CTZ is usually synthesized as a mixture of four diastereomeric racemates, it was not possible to estimate a K d for the LBD-L483Y-N754S:CTZ complex.
